Cyclerion Therapeutics
Biopharmaceutical company focused on developing individualized therapies for central nervous system (CNS) diseases, with a primary focus on treatment‑resistant depression (TRD). Strategy emphasizes leveraging established medicines and novel technologies (including personalized drug delivery with biofeedback) to accelerate clinical validation and regulatory approval. The company also pursues portfolio optimization through out‑licensing and strategic investments.
Industries
Nr. of Employees
small (1-50)
Cyclerion Therapeutics
Cambridge, Massachusetts, United States, North America
Patents
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
US-12275724-B2
View DetailsProcesses and intermediates for the preparation of soluble guanylate cyclase stimulators
US-12030874-B2
View DetailsProcesses and intermediates for the preparation of soluble guanylate cyclase stimulators
US-11708361-B2
View Details
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
US-12275724-B2
View DetailsProcesses and intermediates for the preparation of soluble guanylate cyclase stimulators
US-12030874-B2
View DetailsProcesses and intermediates for the preparation of soluble guanylate cyclase stimulators
US-11708361-B2
View DetailsProducts
Systemic sGC stimulator licensed to external developer (clinical and preclinical data available)
A systemic soluble guanylate cyclase stimulator that has been advanced and licensed to a third party for development in rare kidney disease; demonstrated preclinical tissue distribution and confirmed distribution in clinical studies.
Vascular sGC stimulator positioned for out‑licensing
Clinical‑stage vascular sGC stimulator intended for cardiovascular development and being pursued for out‑licensing to external developers.
CNS‑penetrant sGC stimulators with translational clinical data
Clinical‑stage and preclinical CNS‑targeted sGC modulators developed to preferentially localize to brain and evaluated for effects on cerebral blood flow, brain connectivity, cognitive measures, and relevant biomarkers.
Cyclerion TRD Treatment System
An individualized treatment system for treatment-resistant depression (TRD) using a drug-device combination with biofeedback-controlled delivery of generic IV anesthetics to provide a safer alternative to electroconvulsive therapy (ECT).
CYC-126
Potential to be the first individualized treatment for Treatment Resistant Depression (TRD) using generic IV anesthetics (propofol + dexmedetomidine) with extensive clinical safety experience, and a personalized delivery system operating as a co-pilot to anesthesiologist.
Proprietary Tech-Enabled Personalized Delivery System
A personalized delivery system using biofeedback to potentially optimize anesthetic-based therapy for treatment-resistant depression (TRD).
Systemic sGC stimulator licensed to external developer (clinical and preclinical data available)
A systemic soluble guanylate cyclase stimulator that has been advanced and licensed to a third party for development in rare kidney disease; demonstrated preclinical tissue distribution and confirmed distribution in clinical studies.
Vascular sGC stimulator positioned for out‑licensing
Clinical‑stage vascular sGC stimulator intended for cardiovascular development and being pursued for out‑licensing to external developers.
CNS‑penetrant sGC stimulators with translational clinical data
Clinical‑stage and preclinical CNS‑targeted sGC modulators developed to preferentially localize to brain and evaluated for effects on cerebral blood flow, brain connectivity, cognitive measures, and relevant biomarkers.
Cyclerion TRD Treatment System
An individualized treatment system for treatment-resistant depression (TRD) using a drug-device combination with biofeedback-controlled delivery of generic IV anesthetics to provide a safer alternative to electroconvulsive therapy (ECT).
CYC-126
Potential to be the first individualized treatment for Treatment Resistant Depression (TRD) using generic IV anesthetics (propofol + dexmedetomidine) with extensive clinical safety experience, and a personalized delivery system operating as a co-pilot to anesthesiologist.
Proprietary Tech-Enabled Personalized Delivery System
A personalized delivery system using biofeedback to potentially optimize anesthetic-based therapy for treatment-resistant depression (TRD).
Services
Structuring and executing license and option agreements and partnership arrangements to advance or transition development programs.
Structuring and executing license and option agreements and partnership arrangements to advance or transition development programs.
Expertise Areas
- Neuropsychiatric drug development
- Clinical trial design and execution for CNS indications
- Translational biomarker assessment
- Small‑molecule pharmacology for CNS and vascular targets
Key Technologies
- Soluble guanylate cyclase (sGC) stimulators / sGC pathway pharmacology
- Personalized drug delivery with biofeedback
- CNS‑penetrant small‑molecule therapeutics
- Translational biomarkers for brain function (cerebral blood flow, connectivity)